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abstract
GABAA receptors are important for inhibition in the CNS where neurosteroids and protein kinases are
potent endogenous modulators. Acting individually, these can either enhance or depress receptor
function, dependent upon the type of neurosteroid or kinase and the receptor subunit combination.
However, in vivo, these modulators probably act in concert to ﬁne-tune GABAA receptor activity and thus
inhibition, although how this is achieved remains unclear. Therefore, we investigated the relationship
between these modulators at synaptic-type a1b3g2L and extrasynaptic-type a4b3d GABAA receptors
using electrophysiology.
For a1b3g2L, potentiation of GABA responses by tetrahydro-deoxycorticosterone was reduced after
inhibiting protein kinase C, and enhanced following its activation, suggesting this kinase regulates
neurosteroid modulation. In comparison, neurosteroid potentiation was reduced at a1b3S408A,S409Ag2L
receptors, and unaltered by PKC inhibitors or activators, indicating that phosphorylation of b3 subunits is
important for regulating neurosteroid activity. To determine whether extrasynaptic-type GABAA re-
ceptors were similarly modulated, a4b3d and a4b3S408A,S409Ad receptors were investigated. Neurosteroid
potentiation was reduced at both receptors by the kinase inhibitor staurosporine. By contrast,
neurosteroid-mediated potentiation at a4S443Ab3S408A,S409Ad receptors was unaffected by protein kinase
inhibition, strongly suggesting that phosphorylation of a4 and b3 subunits is required for regulating
neurosteroid activity at extrasynaptic receptors. Western blot analyses revealed that neurosteroids
increased phosphorylation of b3
S408,S409 implying that a reciprocal pathway exists for neurosteroids to
modulate phosphorylation of GABAA receptors.
Overall, these ﬁndings provide important insight into the regulation of GABAA receptors in vivo, and
into the mechanisms by which GABAergic inhibitory transmission may be simultaneously tuned by two
endogenous neuromodulators.
This article is part of the Special Issue entitled ‘GABAergic Signaling in Health and Disease’.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Neurosteroids and protein kinases are among the most potent
modulators of the GABAA receptor, which,when acting individually,
can enhance or depress receptor function depending on the nature
of the neurosteroid or protein kinase present and to some extent,
on the subunit combination of the receptor (Belelli and Lambert,
2005; Moss and Smart, 1996). However, in vivo, these agents are
unlikely to be temporally discrete modulators at GABAA receptors,
and are far more likely to act in concert to achieve high-precision
ﬁne-tuning of inhibitory neurotransmission.
A number of previous studies have indicated that the activity of
protein kinases, and presumably phosphorylation, can modulate
the potentiating effects of selected neurosteroids on both recom-
binant and native GABAA receptors. For example, in Xenopus oo-
cytes expressing recombinant a1b2g2L GABAA receptors, the
potentiation of GABAAreceptor-mediated currentsbythe naturally-
occurring neurosteroid, tetrahydro-deoxycorticosterone (THDOC)
is enhanced by the activation of protein kinase C (PKC)
(Leidenheimer and Chapell, 1997). These results are supported by
other studies showing that inhibition of PKC and/or protein kinase
A (PKA) resulted in a reduction of neurosteroid sensitivity in neu-
rons from both the hippocampus (Harney et al., 2003) and hypo-
thalamus (F  ancsik et al., 2000). However, whilst many studies
Abbreviations: THDOC, tetrahydro-deoxycorticosterone; BIM-I, bisindolylma-
leimide I; PMA, phorbol-12-myristate-13-acetate; THIP, 4,5,6,7-
tetrahydroisothiazolo-[5,4-c]pyridine-3-ol.
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neurosteroid activity at GABAA receptors, other results are appar-
ently conﬂicting. Indeed, whilst the aforementioned studies
collectively show positive regulation of neurosteroid potentiation
by the activity of protein kinases, in both the lamina II neurons of
the spinal cord (Vergnano et al., 2007) and the hypothalamic
neurons of pregnant rats (Koksma et al., 2003), enhancement of
protein kinase activity causes a reduction in the neurosteroid
sensitivity of GABAA receptors. This is supported by a more recent
study demonstrating that, in the pyramidal neurons of the hippo-
campus, kindling causes an increase in GABAA receptor phosphor-
ylation which is accompanied by a concomitant decrease in
receptor sensitivity to THDOC (Kia et al., 2011).
The reasons underling these discrepancies are currently unclear,
but one factor which may affect the relationship between neuro-
steroids and protein kinase activity is the subunit combination of the
GABAA receptor. Although the neurosteroids appear to display only
modest changes in potency across most GABAA receptor subtypes
(Belelli et al., 2002; Herd et al., 2007), phosphorylation by protein
kinases has been shown to differentially alter GABAA receptor func-
tion, depending on the receptor isoform (Moss and Smart, 1996),
which can even distinguish between different receptor b subunits
(McDonald et al., 1998). Therefore, when acting together, it could be
envisaged that protein kinases may modulate the activity of neuro-
steroidsattheGABAAreceptorinamannerthatisdependentuponthe
receptor isoform. This may explain the variation in previous studies
whichhaveutilizeddifferentneuronalpopulationslikelytoreﬂectthe
presence of a mixture of different subsets of GABAA receptors.
In order to examine how protein kinases modulate the activity
of neurosteroids in more detail, we investigated the relationship
between neurosteroids and protein kinases at GABAA receptors
with deﬁned subunit compositions, replicating typical synaptic-
and extrasynaptic-type receptor isoforms, by controlling expres-
sion in a secondary cell line. In addition, by mutating speciﬁc target
residues for protein kinases on GABAA receptor subunits, we unveil
a mechanism by which protein kinases can reciprocally act to
modulate the actions of neurosteroids at these receptors.
2. Methods
2.1. Molecular biology
cDNAs encoding murine a1, a1Q241W, a4, b3, b3S408A, b3S409A, b3S408A,S409A, g2L,
g2LS327A,S343A and d GABAA receptor subunitshave all been describedpreviously (Moss
et al.,1991; Connolly et al.,1996; McDonald et al.,1998; Hosie et al., 2006, 2009). These
cDNA constructs were cloned into the plasmid vector pRK5. The cDNA construct
encoding murine a4S443A was generated by site-directed mutagenesis of the wild-type
a4 subunit gene using standard PCR methods and the following oligonucleotides: For-
ward, gccactcgccctgcatttggatctag and reverse, agctgaccccaaagaagctggc, obtained from
Euroﬁns Genomic.
2.2. Cell culture and transfection
HEK293 cells were cultured in Dulbecco's modiﬁed Eagle medium (DMEM;
Gibco) supplemented with 10% v/v foetal calf serum, 2 mM glutamine, 100 U/ml
penicillin G,100 mg/ml streptomycin and incubated at 37  C in 95% air/5% CO2. Cells
were transfected using the calcium phosphate precipitation method (using 1 mgo f
each subunit cDNAand enhanced greenﬂuorescent protein(eGFP) toa total of 4 mg):
20 ml CaCl2 (340 mM) plus 24 mlo f2   HBS (280 mM NaCl, 2.8 mM Na2HPO4,5 0m M
HEPES, pH 7.2) per 22 mm coverslip. Cells were used for electrophysiology 24e48 h
later. For biochemistry (60 mm culture dishes) cells were transfected with a total of
9 mg of the appropriate cDNA mix.
2.3. Electrophysiology
GABA-activated currents were recorded from transfected HEK293 cells contin-
uously perfused with Krebs solution containing: 140 mM NaCl, 4.7 mM KCl,1.2 mM
MgCl2, 2.52 mM Glucose, 11 mM HEPES and 5 mM CaCl2 (pH 7.4). Whole-cell re-
cordings were performed using patch pipettes (4e5M U) ﬁlled with an internal so-
lution (120 mM KCl,1 mM MgCl2,11 mM EGTA,10 mM HEPES,1 mM CaCl2 and 4 mM
ATP, pH 7.11) in conjunction with an Axopatch 200B ampliﬁer (Axon Instruments).
Cells were voltage clamped at  10 mV and currents ﬁltered at 3 kHz (8 pole Bessel
ﬁlter), digitized (Digidata 1322A, Molecular Devices) and viewed and analysed using
Clampex and Clampﬁt ver 9.2, respectively (Molecular Devices). Cells were contin-
ually monitored for access resistance and discarded if this changed by >20%. Drugs
were rapidly-applied using a modiﬁed U-tube systemwith 10e90 %responsetime of
100e150msec.THDOCwaspreparedasa10mMstock solutioninDMSO,anddiluted
to the appropriate ﬁnal concentration in Krebs. The effect of the DMSO vehicle alone
was negligible. The EC20 GABA concentration was pre-determined by constructing
GABA concentrationeresponse curves and new curves were generated regularly to
adjust for any drift in EC20. The EC20 GABAcurrents were recorded at 2 min intervals.
The neurosteroid-mediated potentiation was measured by co-application of EC20
GABA with 50 nM THDOC, followed by a recovery EC20 GABA response. Recording
ceased if the responses did not return to baseline GABA-activated levels. Subse-
quently, cells were perfused with a protein kinase inhibitor or activator diluted in
Krebssolution,andappliedcontinuouslyviathebath.Theexceptionstothiswerethe
protein kinase G (PKG) inhibitor (KT5823) and protein kinase A (PKA) activator
(cAMP), which were applied via the patch electrode. Stocks of staurosporine (1 mM),
BIM-I (1 mM), KT5823 (3 mM) and phorbol-12-myristate-13-acetate (PMA; 1 mM)
were prepared in DMSO. cAMP (10 mM) was dissolved in distilled water.
2.4. Western blotting
Transfected HEK293 cells were treated with 50 nM THDOC or 100 nM PMA as
appropriateandwerelysedtoisolatetotalprotein.Lysisbufferwassupplementedwitha
combination of protease inhibitors (phenylmethyl sulfonyl ﬂuoride and benzamidine)
and phosphatase inhibitors (20 mM NaF, 10 mM sodium pyrophosphate and 20 nM
calyculinA).EqualamountsoftotalproteinweresubjectedtoWesternblottingtoassess
theexpressionofGABAAreceptorb3andphosphorylatedb3subunits(onS408andS409
residues). Total protein was isolated from each transfected cell culture by homogeni-
sation in ice-cold RIPA buffer, followed by cell disruption with repeated freezeethaw
cycles.Equalamountsoftotalproteinweresubjectedtosodium-dodecyl-sulphate(SDS)
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Blot-
ting was performed using 5% w/v milk, or 0.2% BSA, in 0.1% v/v TWEEN-supplemented
TRIS-bufferedsaline(TBS), with blocking for 1 hatroom temperature (RT),exposure to
primary antibody overnight at 4  C, and secondary horseradish peroxidase (HRP)-
conjugatedantibodyfor1hatRT.Followingincubationwitheachantibody,membranes
were washed 3  (10 min, RT) with phosphate buffered saline (PBS) and imaged using
the ECL detection system (GE Healthcare). Images were quantiﬁed using the Western
blot plug-in on ImageJ software (Version 1.44p, National Institutes of Health, USA).
2.5. Antibodies
The following primary antibodies were used for Western blotting: Rabbit anti-
b3-GABAA receptor (1:1000 dilution, Millipore), Rabbit anti-phospho-b3-GABAA
receptor (1:1000, phosphorylated S408/409 epitope, gift from Dr J Jovanovic, UCL,
UK). A donkey anti-rabbit (1:2500, GE Healthcare) secondary antibody (IgG (H&L))
conjugated to HRP was subsequently used for detection.
2.6. Data analysis and statistics
Peak whole-cell GABA-activated currents were analysed using Clampﬁt ver 9.2.
For protein kinase inhibitor or activator experiments, current responses were
normalized to the ﬁrst response elicited by EC20 GABA. The potentiation caused by a
neurosteroid was measured relative to the preceding response to EC20 GABA and
expressed as a percentage. All concentration response curves were constructed by
plotting mean peak response amplitude against GABA concentration and the data
subsequently ﬁtted with the Hill equation:
I ¼ 1

1 þð EC50=½GABA Þ
n
;
where I ¼ GABA-activated current, EC50 ¼ concentration of GABA inducing 50% of
the maximal current response and n is the Hill coefﬁcient. Data were graphically
represented and analysed using Origin version 6.0 (Microcal). Statistical analyses
were undertaken using GraphPad Instat (v.3) employing either a student's t-test
(two value comparisons) or an ANOVA (three or more value comparisons) followed
by an appropriate post-hoc test (as stated in the text) to compare selected data sets.
3. Results
To examine the effects of phosphorylation by protein kinases on
the potentiation of typical synaptic GABAA receptors by neuro-
steroids, HEK293 cells were transfected to express a1b3g2L
subunit-containing GABAA receptors. Whole-cell recording was
used to assess the magnitude of neurosteroid-mediated potentia-
tion before and after cells were treated with modulators to inhibit
or activate protein kinase activity. Peak currents were recorded in
response to brief (3 s) applications of either EC20 (the concentration
eliciting 20% of the maximal GABA response) GABA alone, (baseline
control responses), or EC20 GABA co-applied with 50 nM of the
neurosteroid, THDOC (the potentiated GABA responses). At this
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rents. Higherconcentrations inthe regionof 1 mMand above induce
proportionately more direct activation of the receptor in the
absence of agonist.
4. THDOC potentiation at a1b3g2L GABAA receptors is
reduced following protein kinase inhibition
To investigate whether neurosteroid-mediated potentiation
could be modulated by protein kinases, cells were treated with
staurosporine (200 nM), selected as it is broad-spectrum non-
speciﬁc protein kinase inhibitor. Staurosporine was also chosen
because it is cell permeable, which allows the potentiation induced
by THDOC to be measured before and after treatment within the
same cell, thus reducing any potentialvariation in results that could
arise from using separate populations of treated and untreated
cells. For each cell, the baseline response to EC20 GABA alone and
the potentiated response after co-application of EC20 GABA and
50 nM THDOC was established under basal conditions (i.e., before
protein kinase inhibitor treatment; Fig.1A). Cells were then treated
with 200 nM staurosporine, applied continuously via the bath
perfusion. After 14 min, the baseline and potentiated responses
were re-measured. To allowa direct comparison of the potentiation
before and after staurosporine treatment, each potentiated
response was normalised to the cell's preceding response to EC20
GABA alone. For control experiments, cells remained untreated for
the duration of the recording and these showed negligible change
in the potentiation elicited by 50 nM THDOC over 30 min
(2.5 ± 7.9%; n ¼ 6; Fig. 1A and C). By contrast, cells treated with
staurosporine exhibited a signiﬁcant decrease in THDOC-mediated
potentiation of 54.8 ± 9.1% (P < 0.05, paired t-test; n ¼ 5; Fig.1A and
C). This decrease inpotentiationwas not caused bya staurosporine-
mediated shift in the GABA concentrationeresponse relationship,
which remained unchanged (data not shown). Notably, the
potentiation byTHDOC was notcompletelyabolished, (45.5 ± 12.7%
remained after staurosporine treatment: Fig.1AeC), indicating that
whilst THDOC-mediated potentiation of recombinant a1b3g2L
GABAA receptors is modulated by protein kinases, the presence of
activated protein kinases per se, is not an absolute requirement for
neurosteroid potentiation.
5. THDOC-mediated potentiation is modulated by PKC
The GABAA receptor is a target for phosphorylation by a number
of serineethreonine protein kinases, including PKA, PKC, PKG and
CaMKII (Moss and Smart, 1996; Brandon et al., 2002). To identify
the roles that speciﬁc protein kinases play in modulating the
potentiation of the GABAA receptor by neurosteroids, we treated
cells with selective kinase inhibitors or activators. PKC activity was
inhibited using 500 nM bisindolylmaleimide I (BIM-I: Fig. 2). Cells
treated with BIM-I (for 40 min) exhibited a signiﬁcant decrease in
THDOC-mediated potentiation (by 43.5 ± 3.8%, P < 0.05, paired t-
test; n ¼ 5; Fig. 2A and C). By contrast, inhibition of PKA with an
inhibitor peptide (500 nM PKAI), or PKG with the selective inhibitor
KT5823 (3 mM), did not alter neurosteroid potentiation
(Supplementary Fig. 1) indicating that potentiation of a1b3g2L
GABAA receptors by THDOC is modulated primarily by PKC. As
observed with staurosporine, the potentiation was not abolished
after BIM-I treatment (Fig. 2), further suggesting that protein ki-
nases are not required for basal potentiation by neurosteroids.
6. Activation of PKC enhances THDOC-mediated potentiation
To further examine the relationship between PKC and neuro-
steroidmodulation of GABAA receptors,the effects of activating PKC
were investigated. For this we used phorbol-12-myristate-13-
acetate (PMA). Cells treated with 100 nM PMA (for 36 min) resul-
ted in a signiﬁcant increase in THDOC-mediated potentiation (by
58.0 ± 18.3%; P < 0.05, paired t-test; n ¼ 6; Fig. 3A). This increase
was not due to a PMA induced shift in the GABA
Fig. 1. Staurosporine reduces THDOCemediated potentiation at a1b3g2L GABAA receptors. (A) Mean peak currents recorded from HEK293 cells expressing a1b3g2L GABAA re-
ceptors in response to EC20 GABA (ﬁlled squares) or EC20 GABA þ 50 nM THDOC (open squares). Cells either remained untreated (upper panel) or were exposed to 200 nM
staurosporine (lower panel). All responses were normalised to the peak current of the ﬁrst EC20 GABA-activated response, recorded 2 min after achieving the whole-cell recording
conﬁguration, designated as t ¼ 0 (100%). (B) Example GABA currents taken at the time points shown as t1et4 in (A, lower panel) alone, or in the presence of 50 nM THDOC (grey
bar), before and after staurosporine treatment (black bar). (C) Bar chart showing the potentiation of EC20 GABA-activated currents by 50 nM THDOC in untreated cells (light grey
bars, measured at 6 and 26 min, respectively; n ¼ 6), or in treated cells before (black bar) and after (grey bar) 200 nM staurosporine (n ¼ 6). All data points represent mean ± s.e.m.
Signiﬁcant results are indicated by * (P < 0.05, paired t-test).
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(data not shown). We also investigated the effects of activating PKA
using cAMP (300 mM) but, contrastingly, this did not signiﬁcantly
alter neurosteroid potentiation ( 9.0 ± 4.4%, P > 0.05; n ¼ 4;
Fig. 3B). These observations support those which used the broad-
spectrum protein kinase inhibitor staurosporine, and selective in-
hibitor BIM-I, and indicate that THDOC-mediated potentiation of
a1b3g2L GABAA receptors is primarily modulated by PKC.
The concentration of neurosteroids present in vivo is not static
but instead undergoes dynamic changes in response to various
physiological and pathophysiological conditions including stress,
pregnancy, the ovarian cycle and ageing (Purdy et al., 1991; Paul
and Purdy, 1992; B€ ackstr€ om et al., 2003; Schumacher et al., 2003;
Maguire and Mody, 2009; Sanna et al., 2009), as well as in
response to administration of selected psychoactive drugs, such as
ethanol, g-hydroxybutyrate (GHB) and anti-depressants including
ﬂuoxetine (Uzunov et al., 1996; Sanna et al., 2004). With this in
mind, we performed similar experiments using varying concen-
trations of THDOC (0.1e100 nM) in order to establish whether PKC
can reciprocally modulate the actions of neurosteroids across a
range of concentrations. Consistent with previous data, THDOC
concentrations of 10 nM and above were able to signiﬁcantly
potentiate a1b3g2L GABAA receptor function (%
potentiation ¼ 12.0 ± 3.5 (10 nM), 66.2 ± 10.0 (50 nM),111.5 ± 17.2
(100 nM); P < 0.05, paired t-test; n ¼ 5e11; Fig. 4). No signiﬁcant
potentiation was observed in cells exposed to 1 nM or less THDOC
(5.3 ± 4.3%, P > 0.05; n ¼ 8; Fig. 4). After treatment with 100 nM
PMA (for 30 min), potentiation by 1,10, 50 and 100 nM THDOC was
signiﬁcantlyenhanced by 102.3 ± 43.2%,152.7 ± 65.4%, 50.8 ± 14.2%
and 34.8 ± 14.2%, respectively (P < 0.05, paired t-test; n ¼ 5e11;
Fig. 4). It therefore seems that phosphorylation by PKC can modu-
late THDOC-mediated potentiation across a broad physiological
range of neurosteroid concentrations likely to be experienced
in vivo. Interestingly, treatment with PMA revealed that potentia-
tion could be elicited by just 1 nM THDOC under conditions of
increased PKC activity, which previously was subthreshold for
potentiation (Fig. 4).
7. Phosphorylation at the b3 subunit is important for
modulating THDOC-mediated potentiation
To explore the mechanism by which PKC modulates the activity
of neurosteroids at GABAA receptors and, in particular, to examine
the involvement of direct receptor phosphorylation in this process,
HEK293 cells were transfected to express a1b3g2L GABAA receptors
containing single or multiple point mutations of consensus phos-
phorylation sites known to be targeted by PKC, namely S408 and
S409 on b3 subunits, and S327 and S343, on g2L subunits. Similar to
the results obtained for wild-type receptors, THDOC-mediated
potentiation at a1b3S408Ag2L, a1b3S409Ag2L (Fig. 5AeC) and
a1b3g2LS327A,S343A (Supplementary Fig. 2) GABAA receptors was
signiﬁcantly reduced after treatment (14 min) with 200 nM staur-
osporine (decrease in potentiation ¼ 36 ± 7.5, 54 ± 6.9% and
50.3 ± 7.5%, respectively, P < 0.05, paired t-test; n ¼ 4e5). By
contrast, cells expressing a1b3S408A,S409Ag2L GABAA receptors
showed no change in the magnitude of the potentiation elicited
( 1.74 ± 8.7%, P > 0.05; n ¼ 5; Fig. 5AeC). This complete removal of
sensitivity to kinase inhibition implies that phosphorylation at the
b3, but not the g2L subunit, is important for the PKC-mediated
modulation of neurosteroid potentiation at a1b3g2L GABAA re-
ceptors. Furthermore, the requirement to remove both S408 and
S409 in order to abolish the staurosporine-induced decrease in
THDOC-mediated potentiation, suggests that phosphorylation at
either b3 S408 or S409 is sufﬁcient to modulate the actions of
neurosteroids at these receptors.
Interestingly, under basal cell conditions (i.e., before staur-
osporine treatment), the magnitude of potentiation elicited by
50 nM THDOC at a1b3S408A,S409Ag2L GABAA receptors was
signiﬁcantly reduced compared to that induced at wild-type
receptors (48.6 ± 10.8% versus 99.1 ± 13.8%, P < 0.05, ANOVA
with Tukey's post hoc test; n ¼ 5e6; Fig. 5A, C). This decrease
may be due to the b3 subunit (wild-type or either of the single
mutants) being basally phosphorylated, a post-translational
modiﬁcation that cannot occur at the doubly mutated subunit.
Therefore, as the magnitude of potentiation was reduced under
Fig. 2. PKC activity modulates THDOCemediated potentiation at a1b3g2L GABAA receptors. (A) Mean peak currents recorded from HEK293 cells expressing a1b3g2L GABAA re-
ceptors in response to EC20 GABA or EC20 GABA þ 50 nM THDOC. Cells either remained untreated or were treated with 500 nM bisindolylmaleimide-I (BIM-I). Responses were
normalised to the ﬁrst EC20 GABA-activated peak response (t ¼ 0 (100%)). (B) Sample whole-cell currents in the presence and absence of 50 nM THDOC (grey bar) before and after
BIM-I treatment (black bar). Representative currents are shown from the time points (t) indicated in (A: lower panel). (C) Bar chart for the potentiation of EC20 GABA-activated
currents by 50 nM THDOC in untreated cells (light grey bars, measured at 6 and 52 min, respectively; n ¼ 6), or in treated cells before (black bar) and after (grey bar) 500 nM
BIM-I treatment (n ¼ 5). *P < 0.05, paired t-test.
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supports the notion that phosphorylation at the b3 subunit is
important for regulating neurosteroid activity at a1b3g2L GABAA
receptors.
8. Phosphorylation by PKC at b3 S408 or S409 is sufﬁcient to
modulate neurosteroid activity
We have shown that THDOC-mediated potentiation at a1b3g2L
GABAA receptors is speciﬁcally modulated by PKC (Fig. 2). We
therefore investigated whether the b3 subunit S408 and S409
residues are targeted speciﬁcally by PKC by using either 100 nM
PMA or 500 nM BIM-I, in order to speciﬁcally activate or inhibit
PKC, respectively. Following treatment with 100 nM PMA, cells
expressing a1b3S408Ag2L or a1b3S409Ag2L GABAA receptors
exhibited signiﬁcant enhancements in THDOC-mediated potentia-
tion (54.6 ± 13.8% and 61.1 ± 37%, respectively: P < 0.05, paired t-
test; n ¼ 4; Fig. 6B), similar in magnitude to the increase observed
at wild-type receptors. By contrast, potentiation at a1b3S408A,-
S409Ag2L receptors was unaffected by treatment with either PMA
(Fig. 6A and B:  7.3 ± 9.0%; P > 0.05; n ¼ 4e5) or BIM-I (Fig. 6C and
D; 1.6 ± 8.3%; , P > 0.05; n ¼ 4e5), indicating that these residues are
important for the modulatory effects of PKC observed previously.
These results support those obtained using staurosproine and BIM-
I, demonstrating that PKC-mediated phosphorylation speciﬁcallyat
b3 S408 and S409 is sufﬁcient to modulate the magnitude of
potentiation elicited by 50 nM THDOC at a1b3g2L GABAA receptors.
The PKC inhibition experiments (Fig. 6C and D) also show that,
under basal cell conditions, the magnitude of THDOC-mediated
potentiation induced at a1b3S408A,S409Ag2L GABAA receptors is
signiﬁcantly reduced compared to that observed at wild-type re-
ceptors (45.7 ± 12.9% compared to 140.6 ± 19.2%, respectively,
P < 0.05, paired t-test; n ¼ 4e5). This supports the idea that basal
phosphorylation at the wild-type receptor, which is eliminated
from the double mutant receptor, results in an apparent enhance-
ment in the level of potentiation elicited by 50 nM THDOC. In
support of this, it is notable that in the PKC activation experiment,
there was a trend for the THDOC (50 nM) potentiation elicited at
wild-type receptors (70.2 ± 17.3% enhancement of the EC20 GABA-
activated current) to be greater than that at a1b3S408A,S409Ag2L
GABAA receptors (48.8 ± 6.5%; Fig. 6B), though this did not reach
signiﬁcance.
Fig. 3. PKC but not PKA increases THDOCemediated potentiation of a1b3g2L GABAA receptor currents. (A & B), Top panels: mean peak currents recorded for a1b3g2L GABAA
receptors expressed in HEK cells in response to EC20 GABA or EC20 GABA þ 50 nM THDOC. Cells were untreated or were treated with 100 nM PMA (A) or 300 mM cAMP (B). All
currents are normalised as in Fig.1. Middle panels: typical GABA currents showing potentiation by 50 nM THDOC (grey bar) before and after PMA (A) or cAMP (B). Currents are taken
at the respective time points (t1-t4, t5-t8). Lower panels: bar charts for the potentiation of EC20 GABA-activated currents by 50 nM THDOC in untreated cells (light grey bars,
n ¼ 4e6) or in treated cells before (black bars) and after (grey bars) 100 nM PMA (A; n ¼ 6) or 300 mM cAMP (B; n ¼ 4) treatment. *P < 0.05, paired t-test.
Fig. 4. Effect of PMA on the potentiation of a1b3g2L GABAA receptor currents by
varying concentrations of THDOC. Bar chart for the mean potentiations of EC20 GABA-
activated responses elicited by THDOC (0.1e100 nM) before (black bars) and after (grey
bars) 100 nM PMA (n ¼ 5e11). All data points represent mean ± s.e.m. *P < 0.05, paired
t-test.
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potentiation
To further explore the requirement for protein kinase activation
in the modulation of GABAA receptors by neurosteroids, the
magnitude of potentiation elicited by 50 nM THDOC was assessed
in cells expressing a1b3S408A,S409Ag2LS327A,S343A GABAA receptors,
effectively eliminating basal PKC-induced phosphorylation at all
known PKC sites within the receptor. Consistent with the protein
kinase inhibition experiments, potentiation was still observed at
these receptors (data not shown), indicating that phosphorylation
by protein kinases is not required for the potentiation of GABAA
receptor function by neurosteroids.
10. THDOC enhances b3 subunit phosphorylation via an
interaction with the GABAA receptor
The experiments conducted throughout this study have focused
on the ability of phosphorylation, by protein kinases, to modulate
the actions of neurosteroids at GABAA receptors. However, this re-
ﬂects just one aspect of this relationship and does not address the
potential for this modulation to be bi-directional, i.e., can neuro-
steroids affect the extent of phosphorylation of the GABAA recep-
tor? To investigate this, Western blot analysis was used to
determine the extent of b3 subunit phosphorylation in HEK293
cells expressing a1b3g2L GABAA receptors, before and after expo-
sure to a neurosteroid. Cells either remained untreated or were
exposed to 50 nM THDOC for 5, 10 or 20 min. Lysates were probed
in duplicate with both b3 and phospho-b3 anti-sera and, for each
treatment group, the level of phosphorylated b3 was normalized to
the corresponding amount of total b3 present. As expected, no
phosphorylated b3 was detected in cells expressing a1b3S408A,-
S409Ag2L (Fig. 7A lane 1) and both b3 and phosphorylated b3w e r e
predictably not detected in cells expressing just a1 and g2L sub-
units (Fig. 7A lane 2), conﬁrming the speciﬁcity of antibodies for
their respective targets.
Experiments performed on untreated cells conﬁrmed that there
is some basal phosphorylation of the b3 subunit when it is co-
expressed with a1 and g2L in HEK293 cells (Fig. 7A lane 3). After
treatment of cells with 50 nM THDOC for 5 min, there was little
change in the level of b3 subunit phosphorylation (10.7 ± 11.6%
increase, P > 0.05; n ¼ 3; Fig. 7A lane 4, Fig. 7B). Atendency towards
increased phosphorylation was detected in cells treated with
THDOC for 10 min (78.7 ± 34.9%, P > 0.05; n ¼ 3; Fig. 7A lane 5,
Fig. 7B), and cells exposed to THDOC for 20 min exhibited a sig-
niﬁcant enhancement in the extent of b3 subunit phosphorylation
of 96.3 ± 27.9% (P < 0.05, ANOVA with Dunnett's post hoc test;
n ¼ 3; Fig. 7A lane 6, Fig. 7B). Of interest, this level of phosphory-
lation was still signiﬁcantly less than that achieved by combining a
slightly longer incubation time of THDOC (30 min) with 100 nM
PMA (Fig. 7A, lane 7). Collectively, these results indicate that
THDOC can enhance b3 subunit phosphorylation, supporting the
presence of a reciprocal transduction pathway in which neuro-
steroids can themselves modulate the phosphorylation of the
a1b3g2L GABAA receptor. This in turn may modify the ability of
speciﬁc kinases to further potentiate the receptor.
In order to examine whether THDOC acts to enhance receptor
phosphorylation through an interaction with the GABAA receptor,
we repeated our experiments using cells expressing a1Q241Wb3g2L
GABAA receptors. We previously determined that this mutation is
critically responsible for the sensitivity of GABAA receptors to
potentiating concentrations of neurosteroid (Hosie et al., 2006). In
untreated cells, basal phosphorylation was still evident at the b3
subunit (Fig. 7C lane 3), indicating that these receptors can be
normally phosphorylated. However, following exposure to 50 nM
THDOC for 5,10 or 20 min, no signiﬁcant alteration in the level of b3
Fig. 5. Residues b3
S408A,S409A mediate the staurosporineeinduced reduction in THDOC potentiation at a1b3g2L GABAA receptors. (A) Mean peak GABA currents for a1b3
S408Ag2L
(top panel), a1b3
S409Ag2L (middle panel) and a1b3
S408A,S409Ag2L (lower panel; all n ¼ 5) GABAA receptors in response to EC20 GABA or EC20 GABA þ 50 nM THDOC. Cells were
treated with 200 nM staurosporine. All responses were normalised as in Fig. 1. (B) whole-cell currents showing potentiation by 50 nM THDOC (grey bars) before and after
staurosporine treatment (black bar) at a1b3
S408A,S409Ag2L GABAA receptors. (C) Bar chart of the potentiation of EC20 GABA-activated currents by 50 nM THDOC before (black bars)
and after (grey bars) staurosporine treatment for a1b3g2L (n ¼ 6), a1b3
S408Ag2L (n ¼ 5), a1b3
S409Ag2L (n ¼ 5) and a1b3
S408A,S409Ag2L (n ¼ 5) GABAA receptors. Data for a1b3g2L is
taken from Fig. 1.* P < 0.05, paired t-test.
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25.0 ± 22.7% and 9.3 ± 27.4%, respectively, P > 0.05; n ¼ 3; Fig. 7C
lanes 4e6, Fig 7D). Notably, 100 nM PMA (30 min) was still able to
signiﬁcantly phosphorylate the a1Q241Wb3g2L receptor (Fig. 7D).
These results suggest that THDOC acts to modulate GABAA receptor
phosphorylation through a direct interaction with the receptor
complex. Furthermore, as the mutation Q241W is sufﬁcient to
eliminate any enhancement in receptor phosphorylation by neu-
rosteroid, it is apparent that occupancy of the potentiating neuro-
steroid binding site is necessary to facilitate this reciprocal
modulation.
Collectively, these results show that a complex, bi-directional
relationship exists between neurosteroids and protein kinases at
the a1b3g2L GABAA receptor, with phosphorylation at the receptor
Fig. 6. Modulation of PKC activity does not alter neurosteroid potentiation at a1b3
S408A,S409Ag2L GABAA receptors. (A & C) Mean peak GABA currents for a1b3
S408A,S409Ag2L (n ¼ 4)
GABAA receptors in response to EC20 GABA or EC20 GABA þ 50 nM THDOC. Cells were treated with either 100 nM PMA (A) or 500 nM Bisindolylmaleimide I (BIM-I; C). (B & D) Bar
charts for the potentiation of EC20 GABA-activated currents by 50 nM THDOC before (black bars) and after (grey bars): PMA (B) in cells expressing a1b3g2L (n ¼ 6), a1b3
S408Ag2L
(n ¼ 4), a1b3
S409Ag2L (n ¼ 4) or a1b3
S408A,S409Ag2L (n ¼ 5); or BIM-I (D) in cells expressing a1b3g2L (n ¼ 5) or a1b3
S408A,S409Ag2L (n ¼ 4) GABAA receptors. Data for a1b3g2L is taken
from Figs. 2 and 3A. *P < 0.05, paired t-test.
Fig. 7. THDOC enhances phosphorylation of b3
S408, S409 by binding to the GABAA receptor. (A,C) Representative Western blots showing the level of b3 subunit phosphorylation in
HEK293 cells expressing (A) a1b3g2L or (C) a1
Q241Wb3g2L GABAA receptors. Cells were either untreated (UT) or exposed to 50 nM THDOC for 5, 10 or 20 min or 100 nM PMA for
30 min (as indicated) and probed with b3 or phospho-b3 anti-sera. Cells transfected with a1b3
S408A,S409Ag2L or a1g2L GABAA receptor subunits were used as controls. (B, D) Bar
charts showing average levels of phosphorylated b3 subunits in cells expressing a1b3g2L (B: black bars; n ¼ 3) or a1
Q241Wb3g2L (D: grey bars; n ¼ 3), in UT cells or after 50 nM
THDOC for 5, 10 or 20 min, or 100 nM PMA (D) for 30 min. *P < 0.05, ANOVA with Dunnett's post hoc test.
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the reverse direction, exposure to neurosteroids enhancing the
extent of receptor phosphorylation.
11. THDOC potentiation at a4b3d GABAA receptors is reduced
by protein kinase inhibition
In order to investigate whether the activity of protein kinases is
also important for regulating the magnitude of neurosteroid
potentiation at extrasynaptic-type receptors, HEK293 cells were
transfected to express a4b3d subunit-containing GABAA receptors.
To ensure that the expressed receptors contained the d subunit,
sensitivity to the agonist, 4,5,6,7-tetrahydroisothiazolo-[5,4-c]pyr-
idine-3-ol (THIP) was examined. THIP has been shown to exhibit
super-agonist activity at d subunit-containing receptors compared
to its partial agonism at abg receptors (Brown et al., 2002;
Storustovu and Ebert, 2006; Mortensen et al., 2010). We therefore
used this agonist as a reliable indicator for the presence of d sub-
units within the receptor complex. The results showed that 100 mM
THIP-induced currents were signiﬁcantly larger than those elicited
by100 mM GABA, indicating incorporation of the dsubunit (data not
shown).
To determine whether the actions of neurosteroids at a4b3d
GABAA receptors could be modulated by the activity of protein ki-
nases, cells were treated with the broad-spectrum protein kinase
inhibitor, staurosproine (200 nM) for 14 min. Staurosporine
signiﬁcantly reduced the potentiation induced by 50 nM THDOC
(decrease: 38.1 ± 5.8%, P < 0.05, paired t-test; n ¼ 9; Fig. 8AeC). We
deduce that the actions of neurosteroids at a4b3d GABAA receptors
can therefore also be modulated by the activity of protein kinases.
Furthermore, as observed with a1b3g2L GABAA receptors, protein
kinases are not required for the induction of THDOC-mediated
potentiation at these receptors, as 50 nM THDOC remained able
to enhance the EC20 GABA-activated current by 83.7 ± 18.5% after
staurosporine treatment (Fig. 8AeC).
A number of studies have reported that GABAA receptors
incorporating the d subunit are more sensitive to the potentiating
actions of neurosteroids (Belelli et al., 2002; Brown et al., 2002;
Wohlfarth et al., 2002). However, in the present study, the magni-
tude of potentiation elicited by 50 nM THDOC at a4b3d GABAA re-
ceptors did not differ signiﬁcantly from that observed at a1b3g2L
receptors (128 ± 23.6% and 99.1 ± 13.8%, respectively, P > 0.05;
n ¼ 5e9; Fig. 8 compared to Fig. 1).
12. Phosphorylation of b3 subunits alone does not account
for protein kinase modulation of THDOC potentiation at
a4b3d GABAA receptors
For synaptic-type a1b3g2L GABAA receptors, the extent of b3
subunit phosphorylation regulates the magnitude of neurosteroid
potentiation (Fig. 5 and 6). Equally, phosphorylation at the b3
subunit may also be important for the modulation of neurosteroid
activity at extrasynaptic-type a4b3d receptors. To this end we
expressed GABAA receptors containing mutant b3S408A,S409A sub-
units, in combination with wild-type a4 and d. Surprisingly,
following staurosporine treatment, a4b3S408A,S409Ad GABAA re-
ceptors still exhibited a signiﬁcant reduction in THDOC-mediated
potentiation (27.2 ± 4.6%, P < 0.05, paired t-test; n ¼ 9; Fig. 9),
comparable to that seen with a4b3d receptors, an effect which was
not observed in the equivalent synaptic-like receptor (Fig. 5C).
Therefore it appears that phosphorylation at the b3 subunit is not
the sole determinant of neurosteroid potentiation by protein ki-
nases in a4b3d receptors. However, staurosporine was notably less
effective at a4b3S408A,S409Ad GABAA receptors compared to a1b3g2L
single mutants (Fig. 5C), with a smaller decrease in potentiation
being observed at these compared to wild-type receptors
(27.2 ± 4.6% versus 38.1 ± 5.8%; Fig. 9B). This suggests that phos-
phorylation at the b3 subunit may play a role in the modulation of
neurosteroid activity at a4b3d receptors, but that phosphorylation
at this subunit is insufﬁcient to completely account for the modu-
latory effects of protein kinases observed at wild-type extra-
synaptic-type receptors. Therefore, phosphorylation at other
residues and/or subunits may also be important for the regulation
of neurosteroid potentiation at this receptor subtype.
Fig. 8. Staurosporine reduces THDOC potentiation at a4b3d GABAA receptors. (A) Mean peak currents for a4b3d GABAA receptors activated by EC20 GABA or EC20 GABA þ 50 nM
THDOC. Cells were either untreated (upper panel) or exposed to 200 nM staurosporine (lower panel). (B) Sample whole-cell currents in the absence and presence of 50 nM THDOC
(grey bar) before and after 200 nM staurosporine treatment (black bar). (C) Bar chart showing the potentiation of EC20 GABA-activated currents by 50 nM THDOC in untreated cells
(light grey bars, measured at 6 and 26 min, respectively; n ¼ 5) or in treated cells before (black bar) and after (grey bar) 200 nM staurosporine treatment (n ¼ 9). Responses were
normalised to the peak current recorded at 2 min. *P < 0.05, paired t-test.
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neurosteroid activity at a4b3d GABAA receptors
Another PKC phosphorylation site is known to exist on the a4
subunit, at serine 443 (Abramian et al., 2010), which is absent from
other members of the a subunit family (Moss et al.,1992; Moss and
Smart,1996). Thisresidue hasrecentlybeen foundtobe responsible
for the increased expression of a4 subunit-containingextrasynaptic
receptors following exposure to neurosteroid (Abramian et al.,
2014). To explore the involvement of a4S443 in the modulation of
neurosteroid potentiation in our study, we used an S443A mutation
to prevent phosphorylation at this site. Similar to the results ob-
tained for a4b3S408A,S409Ad GABAA receptors, cells expressing
a4S443Ab3d exhibited a signiﬁcant decrease in THDOC-mediated
potentiation following treatment with 200 nM staurosporine (for
14 min: 24.5 ± 4.3%, P < 0.05, paired t-test; n ¼ 7; Fig. 10). By
contrast, for a4S443Ab3S408A,S409Ad receptors, staurosporine was
now ineffective as the magnitude of potentiation elicited by 50 nM
THDOC was unaffected by staurosporine treatment (0.9 ± 6.5%,
P >0.05; n ¼ 7;Fig.10). Thus, phosphorylation atboththea4 and b3
subunits must be abolished in order to fully prevent the
staurosporine-induced decrease in THDOC potentiation. This sug-
gests that phosphorylation at both a4 and b3 subunits is important
for regulating neurosteroid activity at a4b3d GABAA receptors.
However, as neurosteroid potentiation was still evident at
a4S443Ab3S408A,S409Ad GABAA receptors, (50 nM THDOC,
89.7 ± 15.3% enhancement of the EC20 GABA-activated current:
Fig. 10), this conﬁrms that, as for the synaptic GABAA receptor
counterpart, phosphorylation by protein kinases is not absolutely
required to induce THDOC-mediated potentiation at extrasynaptic-
like a4b3d GABAA receptors.
14. Discussion
Neurosteroids are potent modulators at the GABAA receptor,
potentiating GABA-mediated responses at low concentrations, and
thereby enhancing levels of inhibition, but also directly activating
the receptor at higher, often non-physiological concentrations
(Belelli and Lambert, 2005). Speciﬁc residues that are common to
all GABAA receptor a subunits are responsible for these potentiating
actions (Hosie et al., 2006, 2009). As endogenous modulators of
GABAA receptor function, neurosteroids play an important role in
mediating the stress response, and inducing anxiolysis or sedation,
a phenotype that may feature during pregnancy or the ovarian
cycle, when neurosteroid levels increase manifold (B€ ackstr€ om et al.,
2003; Belelli and Lambert, 2005; Purdy et al., 1991; Maguire et al.,
2009; Maguire and Mody, 2007). This in turn can induce cyclic
changes in d subunit expression and a concurrent modulation of
tonic inhibition in speciﬁc brain regions such as the dentate gyrus
(Maguire and Mody, 2007). Protein kinases are also potent modu-
lators of GABAA receptor function in a bi-directional manner, ach-
ieved by targeting speciﬁc residues for phosphorylation. One of the
more signiﬁcant modulators is PKC which targets known serine
residues to modulate GABA-mediated responses (Moss and Smart,
1996; Krishek et al., 1994; Lin et al., 1996; Leidenheimer and
Chapell, 1997; Jovanovic et al., 2004; Brandon et al., 2000). Given
that these endogenous modulatory mechanisms operate ubiqui-
tously within and around CNS neurons, it is very likely that they
will interact and may be synergistic in their modulation of GABAA
receptor function, especially during times of stress when neuro-
steroid levels are elevated.
There are many precedents for a positive synergistic interaction
of the naturally-occurring neurosteroid, THDOC, and protein ki-
nases (Leidenheimerand Chapell,1997; F  ancsik et al., 2000; Harney
et al., 2003), though equally there is evidence to the contrary
(Koksma et al., 2003; Vergnano et al., 2007; Kia et al., 2011). This
inconsistency may reﬂect the responses of different receptor sub-
types to both neurosteroids and protein kinases (Belelli et al., 2002;
Herdet al., 2007;Moss and Smart,1996). With this in mind wehave
determined how both typical synaptic- (a1b3g2L) and
extrasynaptic-type (a4b3d) receptor modulation by neurosteroid is
inﬂuenced by the activity of protein kinases typical of neuronal
cells.
We noted in this study that both synaptic and extrasynaptic
recombinant receptor isoforms were equally sensitive to neuro-
steroid, with EC20 concentrations of GABA potentiated by ~100%
with 50 nM THDOC,underlying the consistencyof the THDOC effect
among receptor isoforms. Equally, the potentiated responses of
both receptor types were sensitive to the broad-spectrum kinase
inhibitor staurosporine, which typically inhibited by up to 50%. This
demonstrates a consistent inhibition of the potentiating neuro-
steroid action by protein kinases, and also reinforces the instru-
mental role basal protein kinase activity plays in controlling the
ability of neurosteroids to potentiate at these receptor isoforms.
The similar level of potentiation observedwith both types of GABAA
receptor is not surprising given that the neurosteroid binding site is
conserved on all a subunits (Hosie et al., 2009) and these are
common to extrasynaptic and synaptic receptors. Nevertheless, it is
Fig. 9. Staurosporine reduces THDOC potentiation at a4b3
S408A,S409Ad GABAA receptors. (A) Mean peak currents for a4b3
S408A,S409Ad GABAA receptors in response to EC20 GABA or
EC20 GABA þ 50 nM THDOC. Cells were treated with 200 nM staurosporine. (B) Bar chart showing the potentiation of EC20 GABA-activated currents by 50 nM THDOC before (black
bars) and after (grey bars) staurosporine treatment in cells expressing a4b3d (n ¼ 9) or a4b3
S408A,S409Ad (n ¼ 7) GABAA receptors. Data for a4b3d receptors is taken from Fig. 8.
*P < 0.05, paired t-test.
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affected byother subunits inthe pentamer. However, the sensitivity
of extrasynaptic GABAA receptors to neurosteroids, many of which
will contain d subunits, displays variability, and the underlying
conditions causing this variation are yet to be established (Wang,
2011; Wohlfarth et al., 2002).
By searching for a mechanism, using speciﬁc kinase inhibitors
and activators, we establish that PKC is largely responsible for these
actions on synaptic receptors. Importantly, the activity of PKC is
able to modulate THDOC potentiation over a broad spectrum of
physiological concentrations of this neurosteroid. Candidate resi-
dues for phosphorylation by PKC have previously been identiﬁed as
neighbouring serines 408 & 409 on the b3 subunit (Moss et al.,
1992; McDonald and Moss, 1997). Mutating these residues indi-
vidually in the synaptic-type receptor was insufﬁcient to ablate the
speciﬁc effects of PKC modulation, but substitution of both serines
(b3S408A,S409A) prevented any modulation of THDOC potentiation by
the both PMA and BIM-I. Clearly, both these residues are targeted
by PKC for phosphorylation under both basal and enhanced phos-
phorylation conditions, and in order to establish the enhanced
potentiation observed with 50 nM THDOC. The speciﬁcity of this
synergistic interaction for this synaptic receptor was conﬁrmed by
Western blotting following substitution of S408 and S409, and the
potentiating neurosteroid binding site, a1Q241. Clearly, the phos-
phorylation status of the synaptic receptor (a1b3g2) is very
important in revealing the full effect of THDOC, as increased
phosphorylation enhances the actions of THDOC, whereas inhibi-
tion of phosphorylation impairs it.
Equally, our studies using staurosporine also revealed the same
synergistic mechanism at work for extrasynaptic-like GABAA re-
ceptors (a4b3d). However, for this isoform, modulation of THDOC
potentiation by protein kinase not only occurs via phosphorylation
of S408 and S409 on the b3 subunit, but also occurs simultaneously
via S443 on the a4 subunit, as only on the triple mutant receptor
(a4S443Ab3S408A,S409Ad) is staurosporine ineffective. In fact, the
a4S443 site is exclusively phosphorylated by PKC, rather than by
other kinases (Abramian et al., 2010). It is of interest to note that a1
and a4 subunits can also assemble with b2 subunits (Sieghart and
Sperk, 2002; Olsen and Sieghart, 2009) and the latter are also
substrates for PKC phosphorylation at S410 (Moss and Smart,1996),
which may also inﬂuence the extent of neurosteroid potentiation.
Collectively, our data suggest that THDOC can enhance GABA-
activated currents at both synaptic and extrasynaptic receptors in
a phosphorylation-independent manner, since by inhibiting PKC
activity THDOC potentiation is reduced, though never abolished.
However, as well as being inhibited, THDOC potentiation can also
be augmented by the phosphorylation state of these receptors
through the speciﬁc activation of PKC. Notably, b3S408,S409 and
a4S443 are speciﬁcally targeted by PKC for phosphorylation
(Abramian et al., 2010), and indeed, it has recently been suggested
that THDOC may promote the activity or recruitment of PKC iso-
forms associated with the receptor, especially a4 subunit-
containing receptors, in order to assist receptor phosphorylation
(Abramian et al., 2014). We clearly show that residues b3S408,S409
are both targets for PKC modulation of the THDOC potentiation,
though additionally a4S443 is also key in a4 subunit-containing
extrasynaptic receptors. Current evidence suggests that only the
a4S443 residue of extrasynaptic receptors is targeted for THDOC-
induced phosphorylation by PKC to increase cell surface GABAA
receptor expression/stability, to bring about enhanced tonic (THIP-
activated) currents in hippocampal slices (Abramian et al., 2014).
The contribution made by b3S408,S409 to tonic neuronal currents is
yet to be assessed, though, surprisingly, a1b3 cell surface levels
were unaffected by THDOC. In our current study, total expression
levels of b3 subunits in HEK cells, as part of the a4b3d hetero-
pentameric receptor, were unchanged after THDOC.
In conclusion, we ﬁnd that phosphorylation of residues
b3S408,S409 in addition to a4S443 in extrasynaptic receptors is a
prerequisite for full THDOC-induced potentiation of GABA re-
sponses, and this must involve a signal transduction pathway
linking the ﬁrst a-helical transmembrane domain (M1) in the a
subunits (location of a neurosteroid binding site) with the large
intracellular region between M3 and M4 (sites for phosphoryla-
tion). We may speculate that although the M3-M4 loop lacks a
deﬁning physical structure to date, the interaction between neu-
rosteroids and protein kinases maysuggest this domain has a much
closer association with the membrane based M1-M4. It also argues
that other interacting molecules with the M3-M4 loop (receptor-
Fig.10. Staurosporine reduces THDOC potentiation at a4
S443Ab3d, but not at a4
S443Ab3
S408A,S409Ad GABAA receptors. (A) Mean peak currents recorded from HEK293 cells expressing
a4
S443Ab3d (top panel: n ¼ 7) or a4
S443Ab3
S408A,S409Ad (bottom panel: n ¼ 7) GABAA receptors in response to EC20 GABA or EC20 GABA þ 50 nM THDOC. Cells were treated with
200 nM staurosporine. (B) Bar chart showing the mean potentiation of EC20 GABA-activated currents by 50 nM THDOC before (black bars) and after (grey bars) staurosporine
treatment in cells expressing a4b3d (n ¼ 9), a4
S443Ab3d (n ¼ 7) or a4
S443Ab3
S408A,S409Ad (n ¼ 7) GABAA receptors. Data for a4b3d receptors is taken from Fig. 8.* P < 0.05, paired t-test.
J.M. Adams et al. / Neuropharmacology 88 (2015) 63e73 72associated proteins) and post-translational modiﬁcations (e.g.,
ubiquitination) may also have as yet undisclosed effects on neu-
rosteroid potentiation.
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